Recent industry reports have highlighted past and projected rapid expansion in the DNA diagnostics and genomics markets, driven by liquid biopsies, direct-to-consumer testing, and personalized ...

Illumina (ILMN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of ...

Members of Congress have traded $ILMN stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales. Here’s a breakdown of recent ...

Illumina (ILMN) has been grinding higher over the past month, even though the stock is still down over the past year, raising a simple question for investors: is this quiet rebound worth leaning into?

Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00.

Amid increased competition from China’s MGI Tech, Illumina’s stock (NASDAQ: ILMN) has dropped by 11% in a week. MGI Tech’s DNA sequencers are reportedly gaining market share, and despite a recent ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the ...

Illumina (NASDAQ:ILMN – Get Free Report) had its price objective decreased by stock analysts at Citigroup from $90.00 to $85.00 in a research report issued to clients and investors on Monday,Benzinga ...